Summary
Highlights
Multiple Sclerosis (MS) is a chronic, progressive autoimmune disease that affects the central nervous system, specifically the brain and spinal cord. It involves the immune system attacking and destroying the myelin sheath, which is crucial for smooth and faster signal transmission along nerve cells. This damage leads to blocked nerve impulses, causing muscles to be unable to contract efficiently, resulting in fatigue, weakness, vision changes, and incontinence.
MS assessment findings vary and typically follow a pattern of relapse and remission. Relapse signifies a worsening of neurological symptoms, while remission involves partial or complete recovery. Common symptoms include weakness, fatigue, balance problems, muscle spasms, numbness, blurred vision, diplopia (double vision), bowel/bladder incontinence, constipation, depression, and anxiety. Diplopia is often the earliest symptom, posing an increased risk for accidents, making patient safety a priority.
The hallmark signs of MS are known as Charcot's triad: scanning speech (slow, hesitating, or broken speech), intentional tremors (tremors during movement), and nystagmus (involuntary, rapid, repetitive eye movements, which can be vertical, rotary, or horizontal). Other notable phenomena include Lhermitte's sign, where neck flexion causes an electrical shock sensation, and Uthoff's phenomenon, a temporary worsening of neurological symptoms triggered by heat (e.g., hot temperatures, saunas). MS is triggered by stress, infection, and hot temperatures.
Nursing care for MS focuses on avoiding triggers (stress, infection, excessive heat), managing symptoms, supporting mobility and function, and administering medications. Strategies include planning rest periods for fatigue, scheduling toileting and self-catheterization for bowel and bladder control, increasing fluid and fiber intake for constipation, encouraging assistive devices for weakness and balance issues, coordinating physical and speech therapy, and teaching safety precautions to prevent injuries from sensory and mobility changes.
Medications for MS include disease-modifying drugs (DMDs) to prevent relapse, symptom-relief medications (e.g., anticholinergics for incontinence, muscle relaxants for spasms), and acute relapse treatments like IV glucocorticoids or IV immunoglobulins (IVIG) due to the autoimmune nature of the disease. Monoclonal antibodies (natalizumab, ocrelizumab, ofatumab) suppress immune response, requiring monitoring for infection. Interferon beta (avonex, rebif) regulates immune response; nursing considerations include rotating injection sites, monitoring for depression, and sun protection. IVIG is administered slowly to reduce the risk of thromboembolic complications.
The video concludes by summarizing key autoimmune neuromuscular disorders. Myasthenia Gravis (MG) involves the destruction of acetylcholine receptors, leading to muscle weakness that worsens with activity. Guillain-Barré Syndrome (GBS) attacks peripheral nerves, often triggered by infection, causing ascending paralysis and areflexia. Multiple Sclerosis (MS), as discussed, involves myelin destruction in the CNS, resulting in episodic weakness, numbness, vision changes, and the Charcot's triad (scanning speech, intentional tremors, nystagmus) due to impaired signal transmission.